Detalhe da pesquisa
1.
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Lancet Oncol
; 20(5): 711-718, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30922731
2.
The tumor microenvironment in renal cell cancer.
Curr Opin Oncol
; 31(3): 194-199, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30985497
3.
Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors.
Am J Hematol
; 94(5): 563-574, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30790338
4.
Retraction Note to: Differential modulatory effects of GSK-3b and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
Mol Cancer
; 20(1): 92, 2021 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34130704
5.
Retraction Note to: Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells.
Mol Cancer
; 20(1): 89, 2021 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34116693
6.
Sunitinib activates Axl signaling in renal cell cancer.
Int J Cancer
; 138(12): 3002-10, 2016 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26815723
7.
Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.
Cancer Immunol Immunother
; 65(12): 1523-1532, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27695964
8.
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma.
Oncologist
; 20(6): 617-8, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25986244
9.
Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.
Drug Resist Updat
; 17(4-6): 77-88, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25457974
10.
PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells.
J Cell Mol Med
; 17(3): 377-85, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23387989
11.
Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells.
Mol Cancer
; 12: 17, 2013 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-23497256
12.
Differential modulatory effects of GSK-3ß and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
Mol Cancer
; 10: 115, 2011 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-21929745
13.
High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
J Transl Med
; 9: 220, 2011 Dec 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-22188900
14.
Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer.
BJU Int
; 108(8 Pt 2): E245-9, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21320274
15.
CXCR4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors.
Melanoma Res
; 30(1): 14-25, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31524789
16.
Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors.
Melanoma Res
; 30(2): 219-222, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31634214
17.
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
J Clin Oncol
; 38(26): 2981-2992, 2020 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32167863
18.
Effect of melanoma on immune function in the regional lymph node basin.
Clin Cancer Res
; 14(3): 654-9, 2008 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18245524
19.
The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer.
Clin Cancer Res
; 13(2 Pt 2): 758s-763s, 2007 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17255306
20.
The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells.
Cancer Res
; 66(3): 1611-9, 2006 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16452220